Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a hold rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $63.40.

Several equities analysts recently weighed in on CTLT shares. StockNews.com assumed coverage on shares of Catalent in a report on Monday. They set a “hold” rating on the stock. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th.

Catalent Price Performance

Shares of NYSE CTLT opened at $63.48 on Tuesday. The stock has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a fifty day moving average of $62.24 and a 200-day moving average of $60.47. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the firm posted ($0.10) EPS. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, analysts anticipate that Catalent will post 0.78 EPS for the current year.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Catalent by 1.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after buying an additional 229 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in shares of Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after purchasing an additional 278 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Catalent by 26.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after purchasing an additional 278 shares during the period. Finally, Greenleaf Trust raised its position in Catalent by 10.7% in the third quarter. Greenleaf Trust now owns 4,294 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.